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Angiotensin.induced sodium excretion patterns in cirrhosis: Role of
renal prostaglandins. Changes in renal hemodynamics and sodium
excretion induced by an angiotensin 11 (All) infusion were correlated
with urinary prostaglandin E7 (PGE2) excretion in IS patients with
cirrhosis and ascites. All induced natriuretic responses in 47% and
antinatriuretic responses in 53% of the patients. Natriuresis was accom-
panied by an increase; antinatriuresis by a decrease in PGE2 excretion.
Although there was no change in GFR (C1), renal blood flow (CpAH)
decreased. Patients were clinically indistinguishable. Antinatriuretic
responders tended, however, to have higher baseline POE2 excretion
rates, were more sensitive to effects of prostaglandin blockade, and
were less sensitive to the pressor effect of All. Following partial
inhibition of renal prostaglandin synthesis by indomethacin, All-in-
duced natriuretic responses were attenuated or reversed, and antina-
triuretic responses were accentuated. GFR, RBF, and urine flow rate
markedly decreased in both groups. There was no difference in pressor
sensitivity to All following prostaglandin synthesis blockade. We
conclude that in patients with hepatic cirrhosis, the sodium excretion
pattern induced by an exogenous Alt challenge may depend on the prior
state of intrarenal prostaglandin activity. Our findings also support the
hypothesis that renal hemodynamic parameters in patients with cirrho-
sis and ascites are crucially dependent on renal prostaglandins.
Modalités d'excrétion de sodium sous I'influence de l'angiotensine au
cours de Ia cirrhose: Role des prostaglandines rénales. Les modifications
de l'hëmodynamique rénale et de l'excrétion de sodium induites par une
perfusion d'angiotensine 11 (All) ont été corrëlées avec l'excrétion
urinaire de prostaglandines E2 (PGE2) chez IS malades atteints de
cirrhose ascitique. All a déterminé une natriurése chez 47% des
malades et une antinatriurèse chez 53% des malades. La natriurèse est
accompagnée d'une augmentation et l'antinatriurèse d'une diminution
de l'excrétion de POE,. Bien qu'il n'y ait pas de modification du debit
de filtration glomérulaire (Cir,), Ic debit sanguin renal (CpAH) diminue.
Les malades ne peuvent pas Ctre classes cliniquement dans les deux
types de réponses. Les malades qui rèpondent par une antinatriurèse
ont une excretion basale de PGE2 peu élevée, sont plus sensibles aux
effets du blocage des prostaglandines et sont moms sensibles a l'effet
presseur de All. A Ia suite de l'inhibition partielle de La synthese rénale
de prostaglandine par l'indométhacine, les reponses natriurétiques a
All sont attCnuées ou inversées, et les reponses antinatriuretiques sont
accentuees. Le debit de filtration glomerulaire, Ic debit sanguin renal, et
le debit urinaire diminuent dans les deux groupes. II n'y a pas de
modification de La réponse pressive a All a Ia suite de l'inhibition de
synthése de prostaglandine. Nous concluons que chez les malades
atteints de cirrhose hepatique les modifications de l'excrétion du
sodium induites par All peuvent dépendre de l'état antérieur de
Received for publication November 25, 1980
and in revised form May 25, 1981
0085-253818210021-0070 $01.60
© 1982 by the International Society of Nephrology
l'activité intrarénale de prostaglandine. Nos constatations sont aussi en
faveur de l'hypothese selon laquelle les parametres hemodynamiques
rénaux, chez les malades atteints de cirrhose ascitique, dependent
considérablement des prostaglandines rénales.
Renal salt and water retention invariably accompanies forma-
tion of ascites in patients with cirrhosis, even when glomerular
filtration rate (GFR) and renal blood flow (RBF) are normal.
The pathogenesis of this sodium retention is not completely
understood, and there is no unifying hypothesis to explain all
experimental observations.
Proposed mechanisms include: (1) decreased effective"
extracellular fluid volume, resulting in excessive salt and water
reabsorption at the level of the proximal tubule, secondary to
changes in peritubular physical factors [1, 2]: (2) excessive salt
reabsorption at distal nephron sites caused by hyperaldosteron-
ism [3, 4]; (3) redistribution of RBF with a relative decrease in
outer cortical flow [5, 6]; (4) a combination of the above.
In some patients with severe liver disease, GFR and effective
RBF may fall to low levels and be associated with oliguria and
relative hypotension without specific morphologic changes in
the renal parenchyma, a state clinically known as the hepatore-
nal syndrome.
Throughout this spectrum of renal impairment in liver dis-
ease, the renin-angiotensin-aldosterone system is frequently
activated [7], although in a significant number of individuals
with hepatic cirrhosis, plasma renin activity and aldosterone
levels are found to be within the normal range or even sup-
pressed [8]. Furthermore, increased prostaglandin E2 (PGE)
excretion has been demonstrated in cirrhotic patients [9], and
renal function is adversely affected by inhibiting prostaglandin
synthesis [10]. An interrelationship between the renin axis and
prostaglandins has been demonstrated in various experimental
animal models [11—151.
An unexpected natriuretic response to exogenous angiotensin
II (All) infusion in patients with cirrhosis and ascites was first
reported by Laragh et al [16]. Subsequently, Gutman et al
observed that natriuresis occurred in only half of their cirrhotic
patients given All, whereas antinatriuresis was observed in the
rest [17]. To provide further insight into the interrelationship
between the renin-angiotensin and prostaglandin systems in
patients with hepatic cirrhosis, we have examined the potential
role of renal prostaglandins both in mediating angiotensin 11-
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induced sodium excretion patterns and in maintaining renal
hemodynamics.
Methods
Fifteen patients with the diagnosis of hepatic cirrhosis were
selected from the medical services of the Buffalo Veterans
Administration Center. All had a history of alcohol abuse.
Criteria for admission to the study were the following: (I)
Hepatic cirrhosis by history in all and by liver biopsy in some,
(2) clinical stigmata of cirrhosis, (3) presence of ascites on
physical examination, (4) stable hepatic function by routine
biochemical criteria (5) absence of oliguria and normal concen-
trations of serum creatinine and blood urea nitrogen, and (6)
clinically normal cardiovascular status and absence of hyper-
tension.
All patients were in a marked sodium-retaining state, as
evidenced by their random 24-hour urinary sodium excretion
rates of less than 10 mEq/day, during a low-sodium "house
diet" of about 40 mEq/day. They were transferred to the renal
ward 3 days before the study, where they were maintained on a
daily sodium intake of 40 mEq and fluid allowances of up to
1500 ml. All medications were discontinued at least 7 days prior
to study. An informed consent was obtained in which the nature
of the study was fully explained.
Studies were performed in a fasting state. Renal clearances
were measured during water diuresis by oral ingestion of 1000
cc of water in the hour before the study and maintained by i.v.
administration of 5% dextrose in water at a rate slightly
exceeding the urine output. Accurate urine collection was
assured by an indwelling bladder catheter.
Venous blood samples were obtained at the midpoint of each
10-mm clearance period via an indwelling catheter. A second
indwelling needle in the other forearm was used for continuous
administration of the inulin-PAH sustaining solution in 0.9%
sodium chloride administered by a constant infusion pump
(Harvard Apparatus Inc., Dover, Massachusetts). A second
pump was used for the All infusion dissolved in 5% dextrose
solution (Razel Scientific Instruments, Stamford, Connecticut).
Glomerular filtration rate and effective RBF were measured
by clearance of inulin and paraaminohippurate (PAH), respec-
tively. Blood pressure was measured with a standard cuff
mercury sphygomanometer twice during each clearance period.
Recordings were expressed as mean arterial blood pressure
(MP) calculated by the formula: MP (mm Hg) = (3/5 x diastol-
ic + 2/5 X systolic).
After steady-state water diuresis was established, three con-
trol 10-mm clearance measurements were performed (phase I).
Angiotensin II (Ciba Pharmaceutical Co., Summit, New Jersey)
was then infused at a concentration of 16 ig/ml and at a rate
sufficient to increase the systolic blood pressure by approxi-
mately 10 to 15 mm Hg. Following stabilization of the infusion
rate, three more 10-mm clearances were obtained (phase II).
The All infusion was then stopped. When blood pressure
returned to baseline levels, 50 mg of indomethacin was given
orally. Forty-five minutes after the initial indomethacin dose,
an additional 25 mg of indomethacin was given. Phase Ill was
then begun for three additional clearance periods (partial PG
inhibition phase). Angiotensin II infusion was then restarted at
a rate sufficient to raise the BP to the level recorded in phase II.
After stabilization of blood pressure, three final 10-mm clear-
ance periods were obtained (phase IV).
Urinary PGE2 was measured by radioimmunoassay using a
method previously described [181. Urine specimens were kept
at —20° C until the time of assay. Samples were chromato-
graphed on silicic acid columns to separate the PGE fraction
from other prostaglandins or metabolites, The antiserum used
for the immunoassay was prepared against POE2 in rabbits by
Drs. F. Dray and B. Charbonnel at the Institute Pasteur, Paris,
France. This antibody has a high affinity for PGE2 and a low
affinity for other prostaglandins or their metabolites [19]. Sam-
ples were done in duplicate and were analyzed in a single assay
to preclude between assay variation. Prostaglandin concentra-
tions were determined from a curve obtained by assaying POE2
standards supplied by Dr. J. Pike (Upjohn Inc., Kalamazoo,
Michigan).
Plasma and urine samples were analyzed for inulin by the
direct resorcinol method and for PAH by the method of Smith
et a! [20]. Sodium and potassium were measured by flame
photometry and solute concentration by freezing-point osmom-
etry (Advanced Instruments, Inc., model 3L, Needham
Heights, Massachusetts). Results were expressed as mean
SEM. To analyze statistically the four-phase experiments, the
analysis of variance was used with a random-block method.
Student's t test for unpaired observations also was used as
indicated.
Results
Clinical parameters. Tests of hepatic and renal function
measured during the week prior to study are depicted in Table
I. The first seven patients listed were natriuretic responders to
an All infusion. The remaining eight patients were antinatriu-
retic responders. All patients had moderate impairment of liver
function, but there were no distinguishing biochemical parame-
ters between the two groups. In ten patients, plasma renin
activity measured in the supine position during phase I of the
study averaged 2.3 0.9 (natriuretic) and 1.2 0.3 (antinatriu-
retic) ng/ml/hr. This difference was not significant, P < 0.1.
Renal responses to All: Modification by prostaglandin block-
ade. On the basis of the urinary sodium excretion during the
initial angiotensin infusion (phase II), the 15 patients were
divided into two groups, natriuretic responders (47%) and
antinatriuretic responders (53%), despite a wide range in ob-
served responses (Table 2, Fig. 4). Thus distinction was made
arbitrarily on the basis of UNa V increments or decrements
recorded in phase II, regardless of their magnitude. Table 2
outlines the values of all parameters measured in the four
phases of the study beginning with the patients showing natri-
uretic responses.
Natriuretic responses. Seven patients developed variable
degrees of natriuresis during the initial All infusion. The
increment in urinary sodium excretion ranged from 9% to
approximately 2200% of the baseline (phase I) value. This
spectrum of natriuretic response is demonstrated in Figure 1
(preindomethacmn), where the individual increments in fraction-
al excretion of sodium are shown for each patient. With the
exception of patient 1, when P0 synthesis was inhibited by
indomethacin, reinfusion of A!! in phase IV resulted in an
attenuation or reversal of natriuretic responses previously
observed in phase II, Figure 1 (postindomethacin).
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Table 1. Clinical laboratory parameters
Patient
no.
'
Creatinine
mgldl
Total protein
gidi
Albumin SGOT
gid! mU/mi
Alk.
phosphatasea
mU/mi
Total
bilirubin
mg/di
Hb
g/d!
Hct
%
Natriuretic group
12 1.0 7.2 2.0 75 225 2.5 9.1 28
11 1,0 6.5 2.5 80 130 1.5 12.0 37
10 0.9 7.5 1.6 90 190 1.1 12.2 38
6 0.9 6.5 2.3 40 90 2.3 10.6 33
5 0.9 6.5 3.7 40 100 1.7 11.3 35
4 1.0 6.6 3.2 40 100 1.2 13.6 41
1 1.0 6.3 2.6 52 145 2.6 13.6 40
Mean SEM 1.0 .0 6.7 .2 2.6 .3 60 8
Antinatriuretic group
140 19 1.8 .2 11.8 .6 36 2
2 1.5 7.0 2.5 80 120 2.0 11.7 36
3 1.2 6.5 4.0 115 95 1.5 17.4 56
7 1.2 6.2 3.5 50 130 2.0 12.1 36
8 1.2 6.6 2.6 30 130 1.1 13.2 39
9 1.0 7.5 3.5 25 230 0.4 9.1 29
13 0.8 7.4 2.3 75 180 2.6 14.3 44
14 1.1 6.8 2.6 80 200 5.1 12.8 42
15 0.9 8.4 3.0 65 140 3.3 11.0 37
Mean SEM 1.1 .1 7.0 .3 3.0 .2 65 10 153 16 2.3 .5 12.7 .9 40 3
International units.
Figure 2 depicts mean SEM of UNaV, UpGE,V, GFR, RBF,
and urine flow rate (V) of the natriuretic group. The large
standard error of the mean UNaV in phase II reflects the wide
range in natriuretic response to All. These patients increased
their PGE2 excretion from 906 263 to 1357 268 pg/mm in
phase II, P < 0.05. GFR did not change (93.0 4.8 to
95.0 4.7 mI/mm). RBF fell from 591 72 to 510 75 ml!
mm, P < 0.05. Average urine flow rate, V, did not increase
significantly.
Forty-five minutes following oral administration of indometh-
acm (phase III, Fig. 2), the following changes occurred in
comparison to baseline (phase I): GFR did not change signifi-
cantly, and RBF fell to 516 63 mI/mm (P < 0.05). UPGE,V
decreased to 538 164 pg/mm (P < 0.05). There was no signif-
icant change in UNaV and V. Reinfusion of All (phase IV) failed
to induce the natriuretic responses observed in phase II.
Compared with phase III, UNaV and UPGE,V underwent no
significant changes. The rest of the parameters, however,
decreased significantly: GFR, from 87 5.4 to 51 13.1 ml!
mm; RBF, from 516 to 295 104 mI/mm; and V. from 7.7 2
to 4.4 1.8 mI/mm.
Antinatriuretic responses. Angiotensin H infusion (phase II)
induced a variable decrease in UNaV in eight patients, ranging
from 18% to 88% of their control (phase I) values (Table 2).
Mean UNaV, UPGE,V, GFR, RBF, and V of this group of
patients are presented in Figure 3. Initial All infusion in this
group (phase II) induced a decrement in urinary sodium excre-
tion rate from 126 30 to 45 15 p.Eqlmin, P < 0.001. Al-
though the mean baseline (phase I) UPGE,V tends to be higher
than that found in natriuretic responders (1678 625 vs.
906 263 pg/mm, compare Figs. 2 and 3), All failed to
stimulate PGE2 excretion; in fact, it fell to 475 73 pg/mm,
P < 0.05. Again, GFR did not change in phase II compared
with phase I (Fig. 3), but the effective RBF fell significantly by
23%, P < 0.001. Finally, in contrast to natriuretic responders,
urine flow rate decreased from 11.2 2.0 to 3.8 0.4 mI/mm,
P < 0.001.
In this group, indomethacin (phase III, Fig. 3) induced a
significant decline in all parameters (phase III compared with 1):
GFR and RBF fell to 77 14 and 430 52 mI/mm, respective-
ly. UIcjE,V decreased to 278 48 pg/mm. Both UNaV and V
decreased to 36.5 13 i.Eq/min and 4.4 1 mt/mm, respec-
tively.
Reinfusion of All (phase IV compared with III, Fig. 3)
induced an insignificant decline in UNaV, and a significant
decrease in all other parameters, GFR, RBF, and V showing the
most dramatic decrements (Fig. 3). UPGE,V was further reduced
from 278 48 to 120 60 pglmin, P < 0.05.
In the natriuretic group, changes in CH,O and UKV (Table 2)
are not consistent (phase II) and, therefore, the tubular site of
action of All is uncertain.
In summary, the two groups of patients were found to differ
in prostaglandin excretion and effects of prostaglandmn synthe-
sis inhibition in several ways: (1) Urinary baseline PGE2
excretion tended to be higher in the antinatriuretic group. (2)
All induced opposite PGE2 excretion patterns in the two
groups. (3) In the antinatriuretic group, during phase III,
indomethacin induced a fivefold decrement in UPGE,V along
with a significant decline in all other parameters. In contrast,
the natriuretic group showed only a twofold decrement in
UPGE,V whereas other parameters were also less sensitive to
prostaglandin inhibition.
Pressor response. During control (phase I), mean BP was
93.3 2.4 mm Hg, and there was no difference between the
natriuretic and antinatriuretic responders (Table 2). When infu-
sion of All was terminated at the end of phase II, BP returned
to baseline and remained unchanged following indomethacin
administration (phase III). When compared with natriuretic
patients, the antinatriuretic group was less sensitive to the
pressor effect of All. This is best illustrated in Table 3 where
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Table 2. Cirrhotic patients showing a response to Angiotensin II infusion
Natriuretic responses
95 589 7.5
97 438 5.2
98 407 4.0
15 59 0.32
84 443 13.7
88 382 20.3
80 435 13.5
64 283 8.4
92 538 7.6
94 388 8.6
92 473 5.0
40 154 1.27
120 951 7.2
120 949 15.2
110 830 14.4
103 782 6.0
88 407 6.2
97 447 7.6
74 384 2.9
13 55 0.2
91 732 15.8
87 538 15.6
86 710 11.6
88 561 13.3
81 475 4.1
82 434 6.4
69 373 2.3
40 173 1.6
Antinatriuretic response
61 391 3.16
50 286 2.00
53 374 2.16
36 194 1.13
154 593 18.1
127 391 5.5
158 520 2.9
134 401 1.2
73 461 12.3
75 335 2.8
56 348 1.5
50 204 1.5
74 365 11.4
68 219 2.6
65 230 6.2
34 93 0.4
85 545 9.2
73 327 3.8
66 450 1.3
14 90 0.6
119 560 8.9
129 505 5.1
28 446 7.1
46 173 1.1
77 326 7.5
74 195 4.0
77 340 4.5
5 15 0.6
168 892 18.9
209 949 5.0
113 726 9.12
18 80 1.2
a Phase I is control; phase II, All infusion; phase 111, partial prostaglandin inhibition with oral indomethacin; phase IV, All reinfusion during
prostaglandin synthesis inhibition.
All infusion
rate
Patient no. Phaseo p.g/hr
Mean BP
mm Hg
C1
mi/mm
CPAH
mi/mm
V
,ni/min
UNaV
xEq/min
UpGF,V
pg/inin
UP(iE
pg/mi
UKV
jsEq/min
CH,O
mi/iin
C0
mi/mm
I I — 95
II 0.317 114
III 98
IV 0.634 113
4 I
II
III
IV
—
0.211
0.317
104
127
102
122
5 I
II
III
IV
—
0.634
0.528
90
110
86
110
10 I
II
III
IV
—
0.476
0.528
94
109
104
114
II I
II
III
IV
—
0.424
0.424
84
98
91.3
103
12 I
II
III
IV
—
0.634
0.634
97
107
91
103
6 I
II
III
IV
0.741
0.634
89
103
89
104
2 I
II
III
IV
0.528
0.523
108
117
105
118
3 1
II
III
IV
0.424
0.528
114
123
113
120
7 I
II
III
IV
1.05
1.53
100
107
100
116
8 I
II
III
IV
0.845
0.634
94
108
99
115
II I
II
III
IV
0.527
0.531
82
95
85
101
13 I
II
III
IV
0.424
0.317
83
99
91
109
14 I
II
III
IV
1.05
1.05
85
98
82
99
15 I
II
111
IV
0.424
1.05
82
94
80
92
77 390 52 26 5.50 2.00
98 380 73 30 3.15 2.04
58 190 50 34 2.26 1.72
20 20 62 8 —.01 0.33
130 750 55 90 9.43 4.27
628 1670 82 110 11.20 9.10
157 370 102 90 8.74 4.77
204 430 51 60 5.83 3.08
7.0 310 40 52 5.79 1.95
67 800 93 47 6.71 1.89
2.4 320 73 43 3.25 1.72
7.0 120 94 15 0.66 0.61
8.8 626 87 59 4.63 2.63
13.6 1398 92 46 12.45 2.75
32 480 32 45 11.89 2.51
29.7 672 112 48 3.77 2.16
2.1 470 76 39 5.0 1.22
46.5 870 115 96 6.3 1.35
1.5 240 83 21 2.01 0.92
0.9 60 300 3 0.07 0.11
161 1800 114 72 12.41 3.78
177 2300 147 64 12.14 3.45
113 1440 132 69 9.15 2.80
104 1180 89 64 10.63 2.70
11.3 2000 487 18 2.73 1.40
33.7 2085 326 2 4.79 1.64
5.1 730 370 2 1.17 1.10
4.2 530 331 9 1.12 0.46
6.0 280 89 68 1.81 1.35
3.5 160 80 48 0.75 1.05
2.0 200 95 54 0.99 1.17
4.0 130 115 30 0.44 0.69
214 5650 312 36 14.07 4.09
25 650 181 33 3.83 1.63
23 510 163 46 0.81 2.11
6 530 441 40 —0.01 1.33
198 750 61 63 9.03 3.30
141 370 132 57 0.51 2.32
29 80 35 25 3.31 1.06
90 40 26 31 0.25 1.32
239 2700 237 57 7.60 3.79
44 600 230 33 0.97 1.63
126 320 210 38 3.98 2.24
17 18 45 14 —0.10 0.50
128 880 96 74 5.72 3.41
38 460 121 47 1.73 2.07
17 130 112 31 —0.13 1.43
13 60 100 6 0.16 0.58
30 610 69 84 6.62 2.31
19 360 71 72 2.75 2.31
41 340 50 57 4.45 2.72
7 40 36 17 0.27 0.80
96 960 128 43 9.27 1.98
24 380 95 30 5.71 1.52
26 290 64 30 5.09 0.03
0.3 10 17 1 0.01 0.04
96 1590 84 61 16.07 2.89
65 820 164 59 2.51 2.43
28 360 39 44 7.38 1.72
25 130 108 23 0.97 0.20
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Phase I! Phase III
Natriuretic responders
Fig. 1. Angiotensin 11-induced nairiuretic responses and their modfico-
don following prostaglandin blockade. Each line represents a single
patientdesignated by an arabic number. Fractional excretion of sodium
(CNa/CIn) measured in phase II (pre) or IV (post) prostaglandin block-
ade is expressed as a fraction of that measured in phases 1 and Ill,
respectively. The All-induced changes in CNICI,, do not necessarily
imply a tubular effect because of the large altercations in renal hemody-
namics.
the vascular sensitivity index (VSI) is defined as the increment
in mean BP (mm Hg) divided by the dose of All required to
induce that increment. Before PG inhibition, vascular sensitiv-
ity to infused All was greater in the natriuretic patients
(42.8 12.3 vs. 20.5 34, p < 0.05). After partial PG inhibi-
tion, this difference in sensitivity between the two groups was
lost. But, when the mean VSI was compared within either
group of patients, there was no significant difference before and
after PG blockade.
Correlation between sodium and PGE excretion. Prior to
prostaglandin inhibition, All either evoked an increase or
decrease in both PGE2 and sodium excretion above or below
that measured in phase I. In Figure 4, each solid circle
represents the All-induced fractional increment or decrement
(phase lI/phase I) in sodium (natural log, ordinate) and PGE,
excretion rates (abscissa). A correlation was found between the
change in sodium excretion and the change in PGE2 excretion
(r = 0.84). This implies that the sodium excretion pattern
induced by All follows a spectrum of response associated with
changes in renal prostaglandins.
Discussion
Interruption of avid salt and water retention in the patients
with cirrhosis and ascites, even those with relatively normal
renal function, is achieved with difficulty. Laragh et al [16]
observed that patients with cirrhosis and ascites with normal
renal function underwent variable degrees of natriuresis (incre-
ments from 2- to more than 300-fold) when diastolic blood
pressure was raised 15 to 30 mm Hg by i.v. infusion of All. In
those studies, even subpressor doses of All resulted in marked
natriuresis. This contrasted with normal individuals who re-
sponded to All with an antinatriuresis, as did our antinatriuretic
responders. There were no significant changes in GFR or RBF,
leading those investigators to postulate that All inhibited tubu-
lar sodium reabsorption in patients with cirrhosis.
Several years later, Gutman et al [17] reported in a compara-
ble study that only 50% of their patients with cirrhosis and
ascites responded to an All infusion with a natriuresis. The
remainder decreased their sodium excretion rates. These work-
ers suggested that differences in sodium excretion may be
explained by an alteration of peritubular forces induced by the
systemic pressure effects of All.
Results of the present study do not exclude a direct effect of
All either on renal tubular sodium absorption or on peritubular
forces (via altered renal hemodynamics). Our data, however, do
suggest that the natriuretic action of All, whether it be tubular
or hemodynamic or both, is associated with renal prostaglandin
synthesis and/or release. This hypothesis is supported by the
following observations: (I) There was a parallel relationship
between the change in sodium excretion (either positive or
negative) and the change in PGE2 excretion, best illustrated in
Figure 4. (2) After prostaglandin blockade, the initial response,
whether natriuretic or antinatriuretic, was altered. These obser-
vations do not imply, however, that there is a direct cause-and-
effect relationship between sodium excretion and PGE2 synthe-
sis. Furthermore, the marked variability in PGE2 excretory
values (Table 2) limits our ability to interpret directional
changes in sodium excretion.
It is possible that a prostaglandin-mediated tubular effect may
be a mechanism for the changes in sodium excretion induced by
All. In vitro studies have shown that All enhances proximal
tubular sodium reabsorption in the rat [21], but evidence to the
contrary also exists [221. If All enhances sodium reabsorption
in the proximal tubule of patients with hepatic cirrhosis, we
could postulate that in the natriuretic responders this All effect
is reversed in phase II by stimulated renal prostaglandins. In
addition, PGE2 has been shown to inhibit sodium transport in
isolated rabbit cortical collecting tubules [23] and rat late
proximal convoluted tubules [24].
In our patients, however, the response to All was always
rapid, and there were no progressive changes in sodium excre-
tion from the first to third clearance periods in phases II or IV.
Thus, another explanation appears more likely: Natriuresis or
antinatriuresis during All infusion may be determined by the
relative redistribution of blood flow toward or away from
previously ischemic cortical areas. This redistribution could be
mediated by an augmented PGE2 and/or other released prosta-
glandins, such as PGI2, which via their vasodilatory effect allow
a "pressure natriuresis" to operate. In contrast, the inability to
increase prostaglandin release results in additional vasocon-
striction during the exogenous All challenge (antinatriuresis).
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Fig. 2. Natriuretic responders. Mean
SEM excretion rates (UV) of sodium,
PGE2, urine flow (V), and renal hemody-
namic parameters (GFR and RBF) are
shown in control (phase I), All infusion
(phase 11), following partial PG inhibition(phase III) and during reinfusion of All
under partial PG blockade (phase IV) (N =
7 patients).
Fig. 3. Antinatriuretic responders. Mean
5EM excretion rates for sodium, PGE2,
urine flow (V), and renal hemodynamic
parameters (GFR and RBF) are shown for
phases I, II, Ill, and IV as in Fig. 2 (N = 8
patients).
This interpretation is supported by observations made during
phase IV. That is, the All response becomes more homoge-
neous with respect to sodium excretion. There is attenuation or
reversal of the natriuretic responses (Figs. 1 and 2) and an
exaggeration of the antinatriuretic responses (Fig. 3), along with
a marked reduction of the RBF in both groups. Our data,
however, cannot exclude prostaglandin-independent mecha-
nisms mediating natriuretic responses (phase II). For example,
All could induce a pure "pressure natriuresis" secondary to
increases systemic perfusion pressure if the intrarenal vascula-
ture of natriuretic responders were already maximally constrict-
ed at the outset.
Our antinatriuretic group of cirrhotic patients appears clearly
separate from the natriuretic responders when the following
differences are considered: (I) their tendency for higher base-
line urinary prostaglandin excretion, (2) the opposite effect of
All on prostaglandin excretion, and (3) the greater degree of
prostaglandin inhibition induced by the same dose of oral
indomethacin along with a greater sensitivity of all other
parameters to this inhibitory effect. These particular differences
between the two groups may reflect different states of intrarenal
prostaglandin synthetic capacities in a milieu of hepatic cirrho-
sis, with a critical dependence of renal hemodynamics on a
heightened prostaglandin synthesis in the antinatriuretic group.
Patients with hepatic cirrhosis and ascites have higher prosta-
glandin excretion than normal [9]. In cirrhosis, inferences about
the role of renal prostaglandins in maintaining cortical flow
have been obtained by prostaglandin infusion or by prostaglan-
din synthetase inhibition studies [9, 25]. These studies suggest
that renal prostaglandins may partially counteract the renal
Table 3. Pressor sensitivity of A!! before and after prostaglandin
blockagea
Patient no.
VSI (before)
mm HgIp.g All/mm
VSI (after)
mm Hg! ig All/mm
Natriuretic responders
1 59.9 23.7
4 109.0 63.1
5 31.5 45.5
10 31.5 18.9
11 33.0 27.6
12 15.7 18.9
6 18.9 23.6
Mean SEM 42.8 12.3"
Antinatriuretic responders
31.6 6.3
2 17.0 24.6
3 21.2 13.2
7 6.6 10.5
8 16.6 25.3
9 24.6 30.1
13 37.7 56.8
14 12.4 16.2
15 28.3 11.4
Mean SEM 20.5 3.4" 23.5 5.4
VSI is vascular sensitivity index, the change in mean blood pressure
(mm Hg) divided by the amount of All infused (gImin).
P < 0.05 VSI, comparison of natriuretic to antinatriuretic respond-
ers prior to prostaglandin blockade (before).
cortical constriction usually observed in patients with advanced
cirrhosis. Considerable data is available to support an interrela-
tionship between prostaglandins of the E series and All in the
I
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Fig. 4. Correlation of sodium and PGE2 excretion patterns in response
to angiotensin II. The fractional increment or decrement in sodium
excretion (UNaV) is expressed as a natural log function, In (phase 11/
phase I) on the ordinate. Fractional POE2 excretion is given on the
abscissa. The line was calculated by least squares analysis: In (U NV-Ill
UNaV1) = 1.64 (UFV-lllUpcE,V-I) — l.56; r = 0.84. Note that the
sodium excretion pattens fall into a wide spectrum. After prostaglandin
blockade, this relationship is no longer apparent and most patients now
cluster into the left lower quadrant. (N = IS.)
control of RBF. In the normal canine kidney, PGE,, although it
is produced mainly in the medulla [261, does augment cortical
flow. In contrast, exogenous All reduces cortical flow in
normal rat [27], dog [28], and human [17] kidney, even in
subpressor doses. Several investigators have demonstrated the
release of prostaglandin-like substances into the renal venous
blood following infusion of vasopressor concentrations of All
[11]. Also, when All was added to the extracellular medium of
rat papillae maintained in vitro, an increase in PGE2 synthesis
was observed [29]. Thus, it is reasonable to suggest that the
vasoconstrictor effect of All in the kidney cortex is partially
counteracted by PGE2.
Although renal prostaglandin inhibition by nonsteroidal an-
tiinflammatory agents does not appear to have an adverse effect
on renal hemodynamic parameters in the normal kidney [30,
31], the vasoactive role of PGE2 may be particularly important
in clinical disorders subject to renal vasoconstriction, such as
congestive heart failure [19], and cirrhosis with ascites [91.
It is generally agreed that urinary PGE2 excretion reflects
renal PGE2 synthesis and release [32]. It has been reported,
however, that in the conscious dog POE2 excretion (UPGEV) is
linearly dependent on urine flow rate (V) [33]. Such a relation-
ship is expected for any excreted molecule provided concentra-
Fig. 5. Correlation between percent change ([11—Ill] X 100) in urinary
PGE2 concentration (ordinate) and urine flow (V) (N = 15). Natriuretic
(solid triangles) and antinatriuretic (solid circles) responders are distrib-
uted to the right (net secretion) or to the left (net reabsorption) of the
inuljn concentration pattern (shaded area).
tion (U) does not vary inversely with V (that is, inulin). The
relationship between the angiotensin-induced changes in urine
flow (V) and POE2 concentration (UPGE,) is presented in Figure
5 and compared with changes in urine inulin concentration, a
nondiffusional molecule (shaded area). Note that all natriuretic
responders except one, which falls in the upper limit of the
shaded area, show a pattern indicative of net tubular secretion.
Of particular note, in four of seven natriuretic responders,
angiotensin induces increments in urine POE2 concentration in
spite of increased urine flow. These findings suggest that renal
PGE2 synthesis and/or release is stimulated by All in our
natriuretic patients.
In contrast, in antinatriuretic responders, the reduction in
urine flow during angiotensin infusion, may favor backdiffusion
from the lumen. This may account for the decrease in POE,
excretion (UPGE,V) noted in these patients rather than the 'no
change" anticipated if POE2 generation was incapable of fur-
ther augmentation by All. Thus, antinatriuretic responders
concentrate urine POE2 relatively less than they do inulin (Fig.
5), indicating net tubular reabsorption.
With respect to pressor response to exogenous All, our
patients appear more sensitive than do those previously ob-
served [16, 171. But, in these earlier studies, blood pressure was
raised to slightly higher levels, and patients were not subclassi-
fled. In this study, natriuretic patients were more sensitive to
the pressor effect of A!! than were the antinatriuretic patients.
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Surprisingly, neither group of patients changed pressor sensitiv-
ity following indomethacin administration. This finding con-
trasts with that previously reported in a study by Zipser et al
[9], in which the pressor responsiveness to All was heightened
after a 24-hour interval of treatment with indomethacin. Also,
the dose of All used by those investigators was approximately
twice that used in this study, and the induced mean BP response
of 14 mm Hg was greater than the 10.1-mm-Hg average incre-
ment induced in this study.
Our observations suggest that in hepatic cirrhosis a sensitive
equilibrium may exist between the opposing actions of intrare-
nal prostaglandins (vasodilation) and the intrarenal renin-angio-
tensin system (vasoconstriction). Both the All infusion and
prostaglandin blockade by indomethacin can be viewed as a
potential challenge to this vasoactive equilibrium as well as a
means of unmasking the intrarenal prostaglandin status and/or
synthetic capacity. Indeed, there appear to be at least two
subsets of cirrhotic patients that can be differentiated on the
basis of these maneuvers. The type of renal hemodynamic and
sodium excretion response the patient is capable of mounting to
an exogenous All challenge depends on the ability to augment
renal PG production. Future studies may show that this re-
sponse pattern may have prognostic value.
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